You are here

  • Home
  • Online First
  • Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’

Article Text

Article menu

This article has a Reply. Please see:

Download PDFPDF
Correspondence
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’
  1. Timothée Klopfenstein1,
  2. Vincent Gendrin1,
  3. Thierry Conrozier2,
  4. Aurélie Gerazime3,
  5. Marc Puyraveau3,
  6. Souheil Zayet1
  1. 1Infectious Disease Department, North Franche-Comté Hospital, Montbeliard, France
  2. 2Rheumatology Department, North Franche-Comté Hospital, Montbeliard, France
  3. 3Methodology unit, Clinical Investigation Center INSERM 1431, CHU Besancon, Besancon, France
  1. Correspondence to Dr Timothée Klopfenstein, Infectious Disease Department, North Franche-Comté Hospital, 25209 Montbeliard, France; timothee.klopfenstein{at}hnfc.fr

http://dx.doi.org/10.1136/annrheumdis-2021-220771

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We have read with great interest the study conducted by Ramiro et al1 entitled ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’. This study was among the first publications showing benefit of tocilizumab administration in patients with severe COVID-19-associated cytokine storm syndrome, in July 2020.1 In the same way, we observed a benefit of tocilizumab administration in a cohort of 206 patients during the first wave of the pandemic, in June 2020.2

    We have now more ‘evidence-based medicine’ to discuss tocilizumab’s place in COVID-19. Thus, nine randomised clinical trials (RCTs)3–11 have been published about tocilizumab administration in COVID-19; however, the effects on mortality remain heterogeneous in these trials.12 We recently made a …

    View Full Text

    Footnotes

    • Contributors TK, SZ and VG drafted the manuscript. AG and MP made the statistical analysis. All authors revised the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles